Regeneron Pharmaceuticals (REGN) achieved an
89% return over the past five years, despite some recent stock market
volatility. Wall Street predicts a
50% rise by 2025, with many analysts maintaining
bullish outlooks, and labelling REGN among the top promising
cancer and
genomics stocks. Despite REGN'S recent decline in Q3 and a dip following a negative Eylea 2mg blosimilar preliminary injunction ruling, analysts from companies such as RK Asset Management LLC and Principal Financial Group Inc. have increased their shareholdings, indicating strong faith in the company's future. On the innovation front, the company is pushing boundaries, accomplishing a 100% response rate in a
lymphoma clinical trial and obtaining EU approval for
Dupixent, a treatment for children's EoE. Questions, however, are being raised regarding REGN's
financial prospects, with the accusation of insiders disposing of stocks. REGN has also faced a court case regarding alleged kickbacks. Lingering concerns regarding
financial management and
debt continue to face scrutiny.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 May 2024 07:00:00 GMT to Fri, 03 Jan 2025 23:24:01 GMT -
Rating 7
- Innovation 7
- Information 9
- Rumor 6
